State-of-the-art treatment of systemic lupus erythematosus.

International Journal of Rheumatic Diseases
Yoshiya Tanaka

Abstract

As glucocorticoids and immunosuppressive drugs are non-specific therapeutic agents that cause many adverse reactions, the development of biologicals aiming to control specific molecular targets is anticipated for the treatment of systemic lupus erythematosus (SLE). The antibody targeting B cell-activating factor belonging to the tumor necrosis factor family (BAFF) belimumab was the first biological approved for SLE. At present, many biologicals, such as anifrolumab (anti-type I interferon receptor antibody) and ustekinumab (antibody against interleukin 12/23 [p40]), are in clinical trials. Thus, successful treatments with biologicals targeting "bridging cytokines" produced by dendritic cells, which form a bridge between the innate and acquired immune/autoimmune systems, is of particular interest. Moreover, a phase IIb clinical trial of baricitinib, a low-molecular-weight compound targeting Janus kinase 1/2, in patients with SLE revealed that baricitinib was significantly more effective for relieving arthritis and skin manifestations than placebo, and the trial met the primary endpoint. In the future, it is expected that drugs with better efficacy and safety profiles will be used to apply therapeutic strategies, such as precisio...Continue Reading

References

Nov 17, 2006·Annals of the Rheumatic Diseases·Mikiko TokunagaYoshiya Tanaka
Apr 4, 2012·Annals of the Rheumatic Diseases·Y TanakaK Yamaoka
Jun 8, 2012·Nature Medicine·Zheng Liu, Anne Davidson
Aug 2, 2012·Annals of the Rheumatic Diseases·George K BertsiasUNKNOWN European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association
Apr 18, 2014·Annals of the Rheumatic Diseases·Ronald F van VollenhovenMatthias Schneider
Aug 25, 2016·The New England Journal of Medicine·David J Hunter
Jan 29, 2017·Arthritis & Rheumatology·Richard FurieUNKNOWN CD1013 Study Investigators
Feb 16, 2017·The New England Journal of Medicine·Peter C TaylorYoshiya Tanaka
Aug 10, 2017·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Yoshiya TanakaShingo Nakayamada
May 14, 2019·Seminars in Arthritis and Rheumatism·Yoshiya TanakaShingo Nakayamada
Dec 19, 2019·The New England Journal of Medicine·Eric F MorandUNKNOWN TULIP-2 Trial Investigators

❮ Previous
Next ❯

Citations

Oct 10, 2020·Rheumatology International·Mohammad Mustafa, Yasser Mohammed Bawazir
Apr 4, 2021·Journal of Clinical Medicine·Jo L W LambertReinhart Speeckaert
Sep 2, 2021·Expert Review of Clinical Immunology·Shingo Nakayamada, Yoshiya Tanaka
Sep 25, 2021·Inflammation and Regeneration·Yoshiya Tanaka
Oct 31, 2021·International Journal of Rheumatic Diseases·Yuan XuYue-Rong Ma

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of the Association of Physicians of India
Anjali G RajadhyakshaMilind Y Nadkar
Expert Opinion on Drug Safety
Martin Aringer, Josef S Smolen
© 2021 Meta ULC. All rights reserved